The maker of Ozempic and Wegovy said that after a 68-week trial, obese and overweight patients who took CagriSema and followed a treatment plan lost an average of 22.7% of their body weight compared ...

U.S. stock indexes rallied on Monday as investors looked past worries of potential crude supply disruptions after the United ...

Contest Honors Hospitals for Healing Design, Compassionate Care, and Community ImpactAtlanta, GA, June 23, 2025 (GLOBE NEWSWIRE) -- Soliant Health, a leading healthcare and education staffing provider ...

Novo Nordisk (NVO) and Hims and Hers Health (HIMS) shares are sinking on an ended partnership, with the former also ...

Veteran news presenter Dermot Murnaghan has revealed he is living with stage 4 prostate cancer.The broadcaster, who anchored ...

Novo Nordisk unveiled its latest data for a weight-loss drug candidate, but shares of the maker of Wegovy and Ozempic tumbled ...

Fueled by a sustained boom in sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin. | ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

Asian markets were mixed today amid the escalation in the Middle East. South Korea’s Kospi shed 0.2%, while Japan’s Nikkei ...

After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

Indian benchmark indices, Sensex and Nifty, traded lower on Monday, dragged by concerns over the ongoing tension in the ...

Novo Nordisk is halting its collaboration with Hims & Hers Health over the sale of weight loss drugs, STAT says. The ...